

衛生署藥物辦公室  
藥物註冊及進出口管制部

香港九龍南昌街 382 號公共衛生檢測中心三樓

2319 8458

電話號碼 Tel. No.:

詢問處 Enquiries (852) 2319 8458

傳真號碼 Faxline No. (852) 2803 4962

本署檔號 OUR REF.: DH DO PRIE/7-30/15

(來函請註明此檔案號碼)

(IN REPLY PLEASE QUOTE THIS FILE REF.)

Dear Healthcare Professionals,



DEPARTMENT OF HEALTH  
DRUG OFFICE  
DRUG REGISTRATION AND  
IMPORT/EXPORT CONTROL DIVISION  
3/F., Public Health Laboratory Centre,  
382 Nam Cheong Street, Kowloon, Hong Kong

25 July 2018

**Updates on the recall of valsartan-containing products**

Following the public announcement made by the Department of Health (DH) and the previous letters to Healthcare Professionals on 6 July and 9 July 2018 regarding the recall of five valsartan-containing products, this letter serves to update you the latest situation.

In Hong Kong, there are currently a total of 84 registered pharmaceutical products containing valsartan. Having confirmed with all registration certificate holders of these products, it is noted that apart from the five valsartan products recalled on 6 July, all other products available in local market are not affected.

To recap, the DH instructed two licensed medicine wholesalers, namely Actavis Hong Kong Limited (Actavis) and Hong Kong Medical Supplies Ltd (HK Medical), to recall the following valsartan-containing products:-

Product	Hong Kong Registration Number	Registration certificate holder
Valtensin 160mg tablets	HK-61786	Actavis
Valtensin 80mg tablets	HK-61787	Actavis
Valtensin HCT tablets 160/12.5mg	HK-61784	Actavis
Valtensin HCT tablets 80/12.5mg	HK-61785	Actavis
Valsartan Stada 80mg tablets	HK-60794	HK Medical

The DH through its surveillance system noted that the raw material valsartan produced by a manufacturer in the Mainland and used in certain pharmaceutical products as active ingredient, was found to contain an impurity N-nitrosodimethylamine (NDMA). NDMA is classified as a probable human carcinogen based on results from laboratory tests.

*We build a healthy Hong Kong and  
aspire to be an internationally renowned public health authority*

According to the investigation of the European regulatory agency, the presence of NDMA is unexpected and believed to be related to the change of production method of the valsartan raw material since July 2012. Many countries around the world have recalled the affected products from their market. Recently, the World Health Organization (WHO) has issued an alert about the issue and advised that there may be a shortage of valsartan products due to the incident. For details, please refer to

[https://www.pharmacy.moh.ps/Content/File/BO7cBuvjJdFCgOAJs4tadawq\\_RIPnQIHnzV6VebvzAALLbi6Y.pdf](https://www.pharmacy.moh.ps/Content/File/BO7cBuvjJdFCgOAJs4tadawq_RIPnQIHnzV6VebvzAALLbi6Y.pdf).

According to Actavis and HK Medical, the above products have been supplied to local doctors and pharmacies. The products Valtensin 80mg and 160mg tablets have also been supplied to the Hospital Authority. Both companies have set up hotlines (Actavis: 3188 4288; HK Medical: 2806 3112) to answer related enquiries.

So far, the DH has not received any adverse reactions related to the above products affected by the recall. It is noted that the European regulatory agency is conducting an evaluation on the issue, including the health impacts to patients. The DH will closely monitor the assessment results.

It is expected that the NDMA in the affected products will not cause acute toxicity or immediate health risks. Patients who are taking the above products should not stop taking the medicines, but should seek advice from their healthcare professionals as soon as possible for proper arrangement.

Being a healthcare professional, you may need to give health advice to your patients about the potential risk of the affected products with NDMA and consider prescribing other unaffected valsartan products or alternative treatments to patients. According to the information provided by local suppliers, there are stocks of unaffected valsartan products available in Hong Kong. For the full list of registered valsartan products, please access at Drug Office's website ([http://www.drugoffice.gov.hk/eps/do/en/healthcare\\_providers/search\\_drug\\_database.html](http://www.drugoffice.gov.hk/eps/do/en/healthcare_providers/search_drug_database.html)).

Please report any adverse events caused by drugs to the Pharmacovigilance Unit of the DH (tel. no.: 2319 2920, fax: 2319 6319 or email: [adr@dh.gov.hk](mailto:adr@dh.gov.hk)). For details, please refer to the website at Drug Office under "ADR Reporting": <http://www.drugoffice.gov.hk/adr.html>. You may wish to visit the Drug Office's website for subscription and browsing of "Drug News" which is a monthly digest of drug safety news and information issued by Drug Office.

Yours faithfully,



(Joseph LEE)

for Assistant Director (Drug)